Compare SN & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SN | BIIB |
|---|---|---|
| Founded | 1993 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 24.2B |
| IPO Year | N/A | 1991 |
| Metric | SN | BIIB |
|---|---|---|
| Price | $108.20 | $181.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 23 |
| Target Price | $126.29 | ★ $176.48 |
| AVG Volume (30 Days) | ★ 2.0M | 1.9M |
| Earning Date | 11-06-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.74 | N/A |
| EPS | 4.05 | ★ 10.97 |
| Revenue | $6,084,941,000.00 | ★ $10,065,900,000.00 |
| Revenue This Year | $18.94 | $3.61 |
| Revenue Next Year | $11.59 | N/A |
| P/E Ratio | $26.75 | ★ $16.52 |
| Revenue Growth | ★ 18.87 | 4.77 |
| 52 Week Low | $60.50 | $110.04 |
| 52 Week High | $128.51 | $185.17 |
| Indicator | SN | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 70.08 | 72.92 |
| Support Level | $94.94 | $174.53 |
| Resistance Level | $108.24 | $182.94 |
| Average True Range (ATR) | 4.18 | 5.22 |
| MACD | 2.42 | 0.25 |
| Stochastic Oscillator | 98.42 | 83.54 |
SharkNinja Inc is a product design and technology company that creates 5-star-rated lifestyle solutions through inventive products for consumers around the world. Its product categories include Cleaning, Cooking, Food Preparation, Home Environment and Beauty products. It sells vacuum cleaners, cooking pots, fryers, hair dryers, etc. The SharkNinja Group is expected to carry on the design, production, marketing, and distribution of the Shark and Ninja brands of small household appliances in North America, Europe and other selected international markets (excluding the Asia Pacific Region and Greater China). Currently, the majority of the revenue is derived from the U.S. market.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).